Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
There is currently substantial interest in the regulation of cell function by mammalian target of rapamycin (mTOR), especially effects linked to the rapamycin-sensitive mTOR complex 1 (mTORC1). Rapamycin induces G(1) arrest and blocks proliferation of many tumor cells, suggesting that the inhibition of mTORC1 signaling may be useful in cancer therapy. In MCF7 breast adenocarcinoma cells, rapamycin decreases levels of cyclin D1, without affecting cytoplasmic levels of its mRNA. In some cell-types, rapamycin does not affect cyclin D1 levels, whereas the starvation for leucine (which impairs mTORC1 signaling more profoundly than rapamycin) does. This pattern correlates with the behavior of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1, an mTORC1 target that regulates translation initiation). siRNA-mediated knock-down of 4E-BP1 abrogates the effect of rapamycin on cyclin D1 expression and increases the polysomal association of the cyclin D1 mRNA. Our data identify 4E-BP1 as a key regulator of cyclin D1 expression, indicate that this effect is not mediated through the changes in cytoplasmic levels of cyclin D1 mRNA and suggest that, in some cell types, interfering with the amino acid input to mTORC1, rather than using rapamycin, may inhibit proliferation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 1×
“This protein kinase occurs as two types of complex, that is, mTORC1 and mTORC2 (Wullschleger et al., 2006).”
Regulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545 · cited 1×
“Phosphorylation of Thr37/46 is required for the modification of Thr70 and Ser65, reflecting the hierarchical phosphorylation of 4E-BP1 (see Gingras et al., 2001), and depends upon 4E-BP1’s N-terminal RAIP motif (Tee and Proud, 2002).”
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 3×
“Nonetheless, rapamycin strongly affects cell proliferation, cell growth and angiogenesis (Averous and Proud, 2006; Easton and Houghton, 2006; Mamane et al., 2006; Sabatini, 2006).”
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262 · cited 1×
“S6K associates with translation initiation complexes and phosphorylates eIF4B (Holz et al., 2005; Shahbazian et al., 2006), which might explain these observations.”
Hierarchical phosphorylation of the translation inhibitor 4E-BP1
Gingras, A.-C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., Polakiewicz, R. D., Wyslouch-Cieszynska, A., Aebersold, R., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.912401 · Cited by 883 · cited 1×
“Phosphorylation of Thr37/46 is required for the modification of Thr70 and Ser65, reflecting the hierarchical phosphorylation of 4E-BP1 (see Gingras et al., 2001), and depends upon 4E-BP1’s N-terminal RAIP motif (Tee and Proud, 2002).”
eIF-4E expression and its role in malignancies and metastases
De Benedetti, A., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 728
Kimball, S. R., & Jefferson, L. S. (2006) · The Journal of Nutrition · doi:10.1093/jn/136.1.227s · Cited by 631 · cited 1×
“The single most effective amino acid at regulating mTORC1 is leucine (Kimball and Jefferson, 2006).”
mTOR, translation initiation and cancer
Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209888 · Cited by 607 · cited 3×
“Nonetheless, rapamycin strongly affects cell proliferation, cell growth and angiogenesis (Averous and Proud, 2006; Easton and Houghton, 2006; Mamane et al., 2006; Sabatini, 2006).”
The target of rapamycin (TOR) proteins
Raught, B., Gingras, A.-C., & Sonenberg, N. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121145898 · Cited by 605 · cited 1×
“The best-described targets for mTOR are the ribosomal protein S6 kinases (S6Ks) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1, Raught et al., 2001).”
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis
Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C., & Pandolfi, P. P. (2004) · Nature Medicine · doi:10.1038/nm1042 · Cited by 586 · cited 1×
“Artificial overexpression of eIF4E leads to transformation in cell lines (Lazaris-Karatzas and Sonenberg, 1992) and in animal models (Ruggero et al., 2004).”
Moerke, N. J., Aktas, H., Chen, H., Cantel, S., Reibarkh, M. Y., Fahmy, A., Gross, J. D., Degterev, A., Yuan, J., Chorev, M., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.046 · Cited by 572 · cited 1×
“Alternatively, inhibiting eIF4E/4G binding may be a valuable approach: a small molecule inhibitor of the eIF4E/eIF4G interaction was recently shown to decrease the expression of ‘weak’ mRNAs such as c-myc and inhibit the proliferation of cancer cell lines (Moerke et al., 2007).”
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity
Shahbazian, D., Roux, P. P., Mieulet, V., Cohen, M. S., Raught, B., Taunton, J., Hershey, J. W., Blenis, J., Pende, M., & Sonenberg, N. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601166 · Cited by 531 · cited 1×
“S6K associates with translation initiation complexes and phosphorylates eIF4B (Holz et al., 2005; Shahbazian et al., 2006), which might explain these observations.”
Easton, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 459 · cited 4×
“Nonetheless, rapamycin strongly affects cell proliferation, cell growth and angiogenesis (Averous and Proud, 2006; Easton and Houghton, 2006; Mamane et al., 2006; Sabatini, 2006).”
InfluentialRousseau, D., Kaspar, R., Rosenwald, I., Gehrke, L., & Sonenberg, N. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1065 · Cited by 399 · cited 1×
“…D1 expression: (i) rapamycin treatment eliminates S6K activity in HEK293 cells but does not affect cyclin D1 levels and (ii) elimination of 4E-BP1 is enough to abolish the effect of rapamycin on cyclin D1 expression. eIF4E can mediate nuclear export of the cyclin D1 mRNA (Rousseau et al., 1996).”
Peng, T., Golub, T. R., & Sabatini, D. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5575-5584.2002 · Cited by 395 · cited 1×
“Leucine starvation regulates the transcription or stability of several mRNAs (Bruhat et al., 1997; Peng et al., 2002).”
Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?
Corradetti, M. N., & Guan, K.-L. (2006) · Oncogene · doi:10.1038/sj.onc.1209885 · Cited by 386 · cited 1×
“…roles are those mediated by mTORC1, which is sensitive to the immunosuppressant drug rapamycin. mTORC1 signaling is activated by signaling via phosphatidylinositide 3-kinase and protein kinase B (PKB, also termed Akt) and by the Ras/Raf/ERK pathway (Corradetti and Guan, 2006).”
Hashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivières, S., Mercep, L., & Ferrari, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14424 · Cited by 342 · cited 2×
“The inhibition of cyclin D1 expression by rapamycin was previously attributed to enhanced mRNA and protein degradation (Hashemolhosseini et al., 1998).”
Gera, J. F., Mellinghoff, I. K., Shi, Y., Rettig, M. B., Tran, C., Hsu, J.-H., Sawyers, C. L., & Lichtenstein, A. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309999200 · Cited by 331 · cited 2×
“The control of cyclin D1 mRNA translation is complex, involving both cap-dependent and cap-independent mechanisms (Gera et al., 2004).”
Rosenwald, I. B., Lazaris-Karatzas, A., Sonenberg, N., & Schmidt, E. V. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.12.7358 · Cited by 287 · cited 3×
“Overexpression of eIF4E increases cyclin D1 protein levels (Rosenwald et al., 1993).”
Dostie, J. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.3142 · Cited by 206 · cited 1×
“Entry of eIF4E into the nucleus appears to be mediated by 4E-T (Dostie et al., 2000), which contains a similar eIF4E-binding motif to that in 4E-BP1.”
Wang, X., Beugnet, A., Murakami, M., Yamanaka, S., & Proud, C. G. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.7.2558-2572.2005 · Cited by 205 · cited 3×
“Phosphorylation of Thr37/46 is profoundly inhibited by starving cells of amino acids, which inactivates mTOR signaling (Wang et al., 2005).”
Self-citationBruhat, A., Jousse, C., Wang, X.-Z., Ron, D., Ferrara, M., & Fafournoux, P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17588 · Cited by 200 · cited 1×
“Leucine starvation regulates the transcription or stability of several mRNAs (Bruhat et al., 1997; Peng et al., 2002).”
When translation meets transformation: the mTOR story
Averous, J., & Proud, C. G. (2006) · Oncogene · doi:10.1038/sj.onc.1209887 · Cited by 197 · cited 1×
“Nonetheless, rapamycin strongly affects cell proliferation, cell growth and angiogenesis (Averous and Proud, 2006; Easton and Houghton, 2006; Mamane et al., 2006; Sabatini, 2006).”
Self-citationLazaris-Karatzas, A., & Sonenberg, N. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.1234 · Cited by 168
Albers, M. W., Williams, R. T., Brown, E. J., Tanaka, A., Hall, F. L., & Schreiber, S. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41602-x · Cited by 145 · cited 1×
“Conversely, rapamycin, which induces a G1/S arrest, inhibits the serum-induced increase in cyclin D1 protein (Albers et al., 1993; Hashemolhosseini et al., 1998).”
Tee, A. R., & Proud, C. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.6.1674-1683.2002 · Cited by 139 · cited 2×
“This mutant cannot be phosphorylated and binds ‘constitutively’ to eIF4E (Tee and Proud, 2002; Wang et al., 2005).”
Self-citationGuan, L., Song, K., Pysz, M. A., Curry, K. J., Hizli, A. A., Danielpour, D., Black, A. R., & Black, J. D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610513200 · Cited by 81 · cited 1×
“Previous data suggested roles for S6Ks (Koziczak and Hynes, 2004) and eIF4E/4E-BP1 (Rosenwald et al., 1993; Guan et al., 2007) in the regulation of cyclin D1 expression.”
Koziczak, M., & Hynes, N. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404252200 · Cited by 74 · cited 5×
“In the presence of serum, rapamycin Oncogene only slightly decreased the phosphorylation of several sites in 4E-BP1, but did cause the complete dephosphorylation of S6, another target of mTORC1 (Figure 2a), and the inactivation of the S6Ks (data not shown).”
InfluentialJiang, H., Coleman, J., Miskimins, R., & Miskimins, W. K. (2003) · Cancer Cell International · doi:10.1186/1475-2867-3-2 · Cited by 57 · cited 3×
“…that the overexpression of a ‘constitutively-active’ form of 4EBP1 in MCF7 cells led to cell cycle arrest and decreased the expression of cyclin D1 (Jiang et al., 2003) and that protein kinase C-mediated inhibition of cyclin D1 expression involves the activation (dephosphorylation) of 4E-BP1…”
InfluentialProtein Kinase C α Signaling Inhibits Cyclin D1 Translation in Intestinal Epithelial Cells
Hizli, A. A., Black, A. R., Pysz, M. A., & Black, J. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601959200 · Cited by 50 · cited 2×
“, 2003) and that protein kinase C-mediated inhibition of cyclin D1 expression involves the activation (dephosphorylation) of 4E-BP1 (Hizli et al., 2006).”
Avérous, J., Maurin, A., Bruhat, A., Jousse, C., Arliguie, C., & Fafournoux, P. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.03.077 · Cited by 35 · cited 1×
“Reverse transcription and real-time PCR were performed as previously described (Averous et al., 2005).”
Method
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
“D1 upregulation has been shown to be due to increased CYCLIN D1 mRNA translation as a result of 4E-BP1 inhibition, with the activation of eIF4E also being important [297].”
BackgroundThoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling
Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326
“…4E-BP1 phosphorylation , Sesn2 enhances its interaction with eIF-4E and inhibits expression of growth regulatory proteins, such as cyclin D1 and c-Myc, whose translation is eIF-4E dependent and sensitive to 4E-BP1 phosphorylation (Averous et al., 2007; Averous and Proud, 2006; Mamane et al., 2004).”
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth
Shaw, R. J. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01972.x · Cited by 644
“2006) and promote increased cyclin D1 (Averous et al. 2008).”
BackgroundTargeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Metadata
- Authors
- Averous, J., Fonseca, B. D., & Proud, C. G.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- Proud, C G
- Venue
- Oncogene
- Published
- 2007-08-27
- Volume
- 27
- Issue
- 8
- Pages
- 1106-1113
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2016869069
- Cited by
- 194
- References
- 31
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 11 · 2023: 8 · 2022: 16 · 2021: 10 · 2020: 14 · 2019: 14 · 2018: 13 · 2017: 10 · 2016: 10 · 2015: 11 · 2014: 13 · 2013: 7 · 2012: 9
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- cyclin D1, mTORC1 signaling, 4E-BP1, rapamycin, leucine starvation, mRNA translation, breast cancer, MCF-7 cells, cell proliferation, amino acid signaling
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Antibiotics, Antineoplastic, Breast Neoplasms, Cell Line, Humans, Phosphoproteins, Proteins, Transcription Factors, Signal Transduction, Gene Expression Regulation, Neoplastic, Cell Cycle Proteins, Cyclin D1, Sirolimus, Eukaryotic Initiation Factor-4E, Cell Line, Tumor, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.